Welcome to LookChem.com Sign In|Join Free
  • or
6-chloroimidazo[1,5-a]quinoxaline is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

221025-38-3

Post Buying Request

221025-38-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

221025-38-3 Usage

Chemical structure

Two fused rings (imidazole and quinoxaline), chlorine atom at sixth position

Pharmacological properties

Studied as an anti-cancer agent

Biological activities

Investigated for antimicrobial and antiviral activities

Fluorescent probe potential

Explored for DNA and RNA detection

Importance

Valuable compound for further research and development in therapeutic and diagnostic applications

Check Digit Verification of cas no

The CAS Registry Mumber 221025-38-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,1,0,2 and 5 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 221025-38:
(8*2)+(7*2)+(6*1)+(5*0)+(4*2)+(3*5)+(2*3)+(1*8)=73
73 % 10 = 3
So 221025-38-3 is a valid CAS Registry Number.

221025-38-3Downstream Products

221025-38-3Relevant academic research and scientific papers

Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and?Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors

Patinote, Cindy,Bou Karroum, Nour,Moarbess, Georges,Deleuze-Masquefa, Carine,Hadj-Kaddour, Kamel,Cuq, Pierre,Diab-Assaf, Mona,Kassab, Issam,Bonnet, Pierre-Antoine

, p. 909 - 919 (2017/07/27)

The transcription nuclear factor NF-κB plays a pivotal role in chronic and acute inflammatory diseases. Among the several and diverse strategies for inhibiting NF-κB, one of the most effective approach considered by the pharmaceutical industry seems to be

In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives

Moarbess, Georges,Deleuze-Masquefa, Carine,Bonnard, Vanessa,Gayraud-Paniagua, Stephanie,Vidal, Jean-Remi,Bressolle, Francoise,Pinguet, Frederic,Bonnet, Pierre-Antoine

, p. 6601 - 6610 (2008/12/22)

Imidazoquinoxaline and pyrazoloquinoxaline derivatives, analogues of imiquimod, were synthesized, and their in vitro cytotoxic and pharmacodynamic activities were evaluated. In vitro cytotoxicity studies were assessed against melanoma (A375, M4Be, RPMI-75

Discovery and initial SAR of imidazoquinoxalines as inhibitors of the Src-family kinase p56Lck

Chen, Ping,Norris, Derek,Iwanowicz, Edwin J.,Spergel, Steven H.,Lin, James,Gu, Henry H.,Shen, Zhongqi,Wityak, John,Lin, Tai-An,Pang, Suhong,De Fex, Henry F.,Pitt, Sidney,Shen, Ding Ren,Doweyko, Arthur M.,Bassolino, Donna A.,Roberge, Jacques Y.,Poss, Michael A.,Chen, Bang-Chi,Schieven, Gary L.,Barrish, Joel C.

, p. 1361 - 1364 (2007/10/03)

We have identified a novel series of 1,5-imidazoquinoxalines as inhibitors of Lck with excellent potency (IC50s50s1 μM). Structure-activity studies demonstrate the requirement for the core heterocycle in addition to an optimal 2,6-disubstituted aniline group.

Imidazoquinoxaline protein tyrosine kinase inhibitors

-

, (2008/06/13)

Novel imidazoquinoxalines and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic disorders.

Imidazoquinoxaline protein tyrosine kinase inhibitors

-

, (2008/06/13)

Novel imidazoquinoxalines and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic disorders.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 221025-38-3